Exelixis, Inc. (EXEL)

NASDAQ

$41.37

+$0.49 (1.20%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$41.19$42.07

Open $41.41

52 Week Range

$31.90$49.62

Previous Close $40.88

Market Cap11.09B

Volume2.49M

Avg Volume2.77M

P/E (TTM)16.38

EPS (TTM)$2.53

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Exelixis, Inc.

DEC32025

Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025

Source: Business Wire•12 days ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast its virtual event, Exelixis 2025 R&D Day: Building Next-generation Oncology Franchises, on Wednesday, December 10, 2025, from 1:00 p.m. to 3:30 p.m. ...

NOV62025

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

Source: Business Wire•39 days ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference: Exel...

NOV42025

Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Source: Business Wire•41 days ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeli...

OCT282025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

Source: PRNewsWire•48 days ago

NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at [email protected] or 64...

OCT232025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

Source: PRNewsWire•53 days ago

NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at [email protected] or 64...

OCT212025

Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Source: Business Wire•55 days ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management w...

OCT202025

Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet

Source: Business Wire•57 days ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients wi...

OCT182025

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025

Source: Business Wire•59 days ago

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) versus placebo in patients with previously treated advanced neu...